Introduction

Rationale for Proton Therapy
Proton beam therapy is a technologically advanced means of achieving extremely precise radiation dose distributions, resulting in less dose to the normal tissues surrounding the target volume than is typically achievable with conventional x-ray or electron beam therapy. As a result, higher doses can be safely delivered to target volumes which are adjacent, or close to critical normal structures which are vulnerable to radiation injury. Higher doses to the malignant cell population should yield an increased probability of local tumor control (Suit et at., 1990; Thames et al., 1992) . Achievement of local tumor control is essential in cancer therapy and has important practical consequences for the survival of cancer patients.
To illustrate the importance of the problem, in 1980, 1.2 million new cancer cases were diagnosed in the countries of the European Union (Davis et ai., 1990; Doll, 1990; Muir and Boyle, 1990 ). Among them, 65% presented with apparently localized tumors. About two-thirds ofthese are cured by surgery, radiation therapy or a combination of both techniques. Unfortunately, local failure occurred in about one-third of the patients who still had apparently localized disease at the first consultation (Devita, 1983; Devita and Korn, 1986) . Even more pessimistic data were reported by Silverberg et ai. (Silverberg et al., 1990) and Devita et at. (Devita et ai., 1989) .
Therefore, it can be expected that if local failure could be reduced by 50%, cure rates could be improved by 10-15% (Suit, 1982; Suit and Miralbell, 1989) . Continued improvement in survival would be expected to result from the implementation of systems of radiation treatment that provide better physical dose localization, thereby permitting higher dose to regions of disease while maintaining or reducing complications resulting from the irradiation of normal tissues.
As a consequence of their excellent physical dose localization properties, protons are indicated for the treatment of tumors which are close to critical normal structures. In such cases, conventional irradiation techniques often cannot achieve adequate tumor control due to the limitations imposed by normal tissue tolerance.
Protons are also indicated for localized tumors where other treatment modalities, such as surgery, are judged likely to result in unacceptable patient morbidity. Reduced normal tissue doses have the potential of reducing the side effects of multi modality therapy when radiation, surgery and/or chemotherapy are used. Proton beam therapy should be considered where preservation of organ function could be compromised by alternative therapeutic strategies (Suit and Urie, 1992; Wambersie et at., 1992) .
Protons traverse relatively straight paths through a medium, slowing down continuously due to interactions with electrons. A fraction of the protons will suffer nuclear interactions, in which they are effectively removed from the beam. A depth dose distribution for a monoenergetic proton beam (Figure 1 .1) shows a region of dose! rising slowly with depth, called the "plateau", followed by a dose maximum called the "Bragg peak," with an amplitude three to four times the entrance dose (Shipley et at., 1979) .
Beyond the Bragg peak, dose rapidly approaches zero. A superposition of Bragg peaks, created by varying the energy (a technique known as energy modulation) yields a region of relatively uniform high dose, often called a spread-out Bragg peak (SOBP), which can be designed to have a width sufficient to cover the target volume. The SOBP dose still falls rapidly towards zero beyond the distal target edge, although modulation also has the effect of increasing the entrance dose relative to an unmodulated beam. By varying the energy of the protons throughout the beam cross-section, or by placing absorbers of varying thickness between the beam source and a patient, it is possible to conform the distal edge of the high dose region to the distal edge of the target volume. This technique is usually referred to as energy-or range-modulation. In addition, dynamic beam delivery systems may be employed to conform the dose to the proximal edge of the target volume (see Section 2.3). Beams from several directions may be used to produce dose distributions that are conformal with the 3-dimensional shape of the target volume. Clinical results confirm the benefits of this approach (Gragoudas et at., 1982; Suit et at., 1982a; Suit et al., 1982b; Minakova et at., 1983; Austin-Seymour et al., 1985; Munzenrider et at., 1985; Saunders et at., 1985; Austin-Seymour et al., 1989; Austin-Seymouret al., 1990) .
The technology for development of proton treatment facilities is readily available. The principles of operation of proton accelerators capable of producing beams with energies in the range of 250 MeV are well understood and examples of such accelerators are being used for proton radiation therapy (see Table 1 .1). Computer control systems provide the simplicity of operation required for a hospital setting. The technology of beam delivery systems, including rotating gantries, is well developed. Threedimensional diagnostic imaging, particularly computed tomography (CT) and magnetic resonance imaging (MRI), is readily available and provides the basis for tissue delineation and assignment of tissue properties for proton beam treatment planning. Three-dimensional treatment planning systems offer capabilities for simulation and optimization of patient treatments and the design of patient-specific beam apertures and tissue compensators (Goitein and Abrams, 1983; Goitein et at., 1983; Goitein and Miller, 1983) . Numerically controlled machine tools are available for fabricating patient-specific devices from data generated by the treatment planning system (Wagner, 1982) . In addition, since normal tissues are significantly spared by the dose distributions of proton beams, greater flexibility is available for optimization of the treatment delivery schedule.
The relative biological effectiveness (RBE) of proton beams compared to 60CO gamma-rays is only slightly greater than unity. Most of the RBE measurements for protons give values ranging from 1.0 to 1.2 relative to 60CO gamma-rays (Robertson et al., 1975; Urano et al., 1984; Robertson et al., 1994; Gueulette et at., 1996) . This rather large range of values could be due to differences in biological systems, end points, proton beam characteristics, tissue depth, dosimetry methods or experimental uncertainties. No significant biological differences are expected from such a small RBE, so the clinical experience accumulated with x rays can be extrapolated to protons, especially that related to normal tissue tolerance (Suit et at., 1980) . A weighting factor of1.1 is typically applied to proton doses to account for RBE effects, yielding a dose which should be biologically equivalent to x rays.
History of Proton Therapy
The use of proton beams for treatment of human disease was first suggested by R. R. Wilson in 1946 (Wilson, 1946 . At that time, Wilson recognized that accelerators capable of generating proton beams with sufficient energy to provide a range in tissue comparable to body dimensions, were under construction. Wilson noted that the mass of the proton would cause it to travel in a nearly straight path through tissue and that the energy deposition pattern of a proton beam would produce high radiation doses near the end of the range in a relatively narrow region, now referred to as the Bragg peak ( Figure  1.1) . Wilson proposed the irradiation of localized regions within the body with proton beams to provide maximum sparing of surrounding tissues. In his 1946 paper, Wilson proposed that rotating modulator wheels could spread the Bragg peak over large targets, transmission ionization chambers could be employed to monitor patient dose and ionization chambers could provide absolute dose calibration.
By 1954, C. A. Tobias and his associates at the University of California at Berkeley had completed animal irradiation studies and began small-field treatment of the human pituitary gland with a 340 MeV proton beam from the 184 inch cyclotron (Tobias et at., 1955; Tobias et al., 1958) . Initially, crossfired beams penetrating through the entire head were used, followed by the first application of Bragg peak treatment. Mter 1957, these treatments were converted to deuterons and alpha particles. A total of 274 patients had been treated by 1964 with 190 MeV deuterons, 340 MeV protons or 900 MeV alpha particles (Tobias et aZ., 1964) . This project continued to contribute knowledge, interest and technical advances essential to proton therapy (Castro et aZ., 1985) until the shutdown of the cyclotron in 1987 followed by that of the Bevalac accelerator in 1992, by which time approximately 2000 patients had been treated with protons, deuterons and alpha particles.
Inspired by the work at Berkeley, B. Larsson began the development of proton therapy as a neurosurgical tool at the Gustaf Werner Institute in Uppsala, Sweden (Larsson et aZ., 1958; Larsson et aZ., 1959; Leksell et aZ., 1960; Larsson, 1961; Larsson et aZ., 1963; Larsson et aZ., 1974) . Following the neurosurgical work, the first proton treatments with large fields, the first use of a scanned proton beam delivery system and the first proton treatments with a modulated Bragg peak were developed at Uppsala (Graffman et aZ., 1967; Larsson, 1967; Graffman and Jung, 1970; Graffman et aZ., 1975) . By 1970, a total of 69 patients had received large-field, energy-modulated proton treatments to disease sites in many locations within the body (Graff man et aZ., 1985) . This facility resumed operation in 1988 following a period of extensive equipment upgrade (Montelius et aZ., 1991) .
In 1961, R. N. Kjellberg and associates (Kjellberg et aZ., 1962; Kjellberg et aZ., 1983) began treatment of human intracranial tumors at the Harvard Cyclotron Laboratory (HCL) using a 160 MeV proton beam. Large-field fractionated proton therapy began at HCL in 1974 with a beam delivery system employing rotating range modulator wheels (Koehler et aZ., 1975) , passive scattering (Koehler et aZ., 1975) , and shaped range compensators (Wagner, 1982) . Methods for three-dimensional treatment planning of proton treatments were developed at Massachusetts General Hospital (Goitein and Abrams, 1983; Goitein et aZ., 1983; Goitein and Miller, 1983) . Dosimetry methods were formulated (Verhey et aZ., 1979) and techniques for patient positioning were developed (Verhey et aZ., 1982) . These systems allowed highprecision, high-dose radiation therapy with proton beams for many disease sites (Suit et aZ., 1975; Suit et aZ., 1977; Suit et aZ., 1980; Suit et aZ., 1982b) including proton treatment of ocular melanoma (Constable and Koehler, 1974; Gragoudas et aZ., 1977) . By 1991 over 5000 patients had been treated at the Harvard facility with extensive follow-up (KIiman et aZ., 1984; Austin-Seymour et aZ., 1985; Munzenrider et aZ., 1985) inspiring world-wide interest in the development of hospital-based proton treatment centers.
Three facilities for proton treatment were developed in the former Soviet Union. The Joint Institute for Nuclear Research (JINR) in Dubna began treating patients in 1968 with beam energies up to 200 MeV from a 680 Me V synchrocyclotron. This was followed in 1969 by the initiation of proton therapy at the Institute of Theoretical and Experimental Physics (lTEP) in Moscow, where five beam energies ranging from 70 MeV to 200 MeV can be selected from a 10 GeV synchrotron. By 1987, 1360 patients with disease in a variety of sites had been treated (Minakova, 1987) . The Leningrad Institute of Nuclear Physics (LINP) at Gatchina began treatment with a 1000 MeV proton beam in 1975. Intracranial treatment of 508 patients using cross-fire irradiation with small fields in a single fraction were reported (Raju et az', 1987) . Summaries of the former Soviet Union proton treatment experience and facilities may be found in several publications (Boone et al., 1977; Riabukhin, 1982; Abrosimov et aZ., 1985; Graffman et aZ., 1985) .
Treatment with negative pions provided important technical innovations that influenced the continued development of proton therapy. A pion treatment facility at The Los Alamos Scientific Laboratory in the USA operated from 1974 to 1981 (KIigerman et aZ., 1979) joined by the development of pion treatments at the Swiss Institute for Nuclear Research (SIN) now known as the Paul Scherrer Institute (PSI) in Villigen, Switzerland (Vonessen et aZ., 1982) and the TRIUMF laboratory in Vancouver, B.C. Canada (Goodman et aZ., 1985) . At PSI, multiple pion beams were focused onto a single stationary spot and the patient was moved within a cylinder of water according to a planned pattern to deliver a dose distribution that conformed to the defined target volume. Developments from pion therapy that are important for proton treatment include threedimensional conformal techniques for beam delivery, patient immobilization and positioning methods and the development of treatment planning tools for conformal radiation therapy.
Two facilities for proton therapy were established in Japan (Tsunemoto et aZ., 1985) . In 1979 the National Institute for Radiological Sciences at Chiba began clinical trials for treatment of superficial lesions with a 70 MeV beam. This facility was the first to develop a spot scanning system for the delivery of proton beams (Kanai et aZ., 1980) . The Proton Medical Research Center (PMRC) in Tsukuba began treatment with a 250 MeV beam in 1983 and by July, 1995 had treated 462 patients. The PMRC facility produced a clinical proton beam by energy degradation from 500 MeV. This facility was the first to provide a vertical proton beam and the first to make use of a multivane collimator for proton therapy (Matsuda and Inamura, 1981). 
Location
Proton Period a tumors were initiated in 1994 with a fixed, horizontal beam. In Nice, France, the hospital based cyclotron of the Centre Antoine Lacassagne, initially designed for neutron therapy, is now used for neutron and proton therapy. Using 65 MeV protons, 1,010 uveal melanomas have been treated through 1997.
The first hospital-based center designed specifically for proton therapy was established by James Slater at Lorna Linda University Medical Center in California (Slater et al., 1988; Slater et al., 1991) . Treatment beams for four therapy rooms and a research room are produced by a variable-energy 250 MeV synchrotron designed and built at the Fermi National Laboratory specifically for proton treatment. The first patient was treated in October, 1990. By 1991, proton beams varying from 100 MeV to 200 MeV were in clinical use on two horizontal beam lines and the 200 MeV line was upgraded to 250 MeV in 1992. The first isocentric beam delivery system employing a rotating gantry was commissioned for patient treatment at Lorna Linda in June, 1991 with beam energies of 155,200 and 250 MeV. Two additional gantry treatment rooms were commissioned in 1994. The facility at Lorna Linda provides largefield fractionated treatments, treatment of ocular melanoma and stereotactic radio surgical techniques with a total capacity of approximately 100 patient treatments per day. By July of 1998, over 3400 patients had been treated in this facility. Table 1 .1 lists proton therapy facilities around the world, the number of patients treated, the proton energy, the date of first treatment and the date for which the treatment numbers are recorded. As of the middle of 1998, in excess of21,500 patients had been treated with protons worldwide, a number which is growing at a rate of approximately 2000 patients per year (Sisterson, 1995) . This increase in the number of facilities and the growing clinical activity underscores the need for standardization of dosimetry.
Scope of this Report
The development of accurate and uniform standards for radiation treatment dosimetry has been a continuing effort since the earliest days of radiotherapy. Recommended techniques for the dosimetry of photon and electron beams have been developed (NCRP, 1981; AAPM, 1983; IAEA, 1987) and continue to evolve. The expanding capabilities for treatment with proton beams must be met with corresponding efforts in standardizing accurate dosimetry methods. This ICRU Report is intended to promote uniformity of standards that will provide a basis for world-wide comparison of clinical results and allow the development of meaningful clinical trials.
This Report describes current practice in proton therapy and recommends standards for the dosimetry of proton treatments. Established proton treatment facilities might use this Report as a source of information for the maintenance of accurate standards. New facilities may build their procedures from recommendations found in this Report and planners of new facilities may examine alternatives within current practice for the production and monitoring of treatment beams. This Report will be published in two separate parts. Part I includes a description of the interaction of protons with matter, various methods of beam production, the characteristics of proton beams in clinical use, current methods for beam monitoring and specific recommendations for dose calibration. Part II, to be published at a later time, will deal with the influence of patient shape and tissue heterogeneity on dose distribution, a description of treatment planning considerations, a definition of beam quality in relation to microdosimetry and a discussion of the clinical radiobiological effectiveness (RBE) of proton beams relative to photon beams.
Relation to Existing Reports
The American Association of Physicists in Medicine produced AAPM Report 16, "Protocol for Heavy Charged Particle Therapy Beam Dosimetry,"in 1986 (AAPM, 1986 . That report was prepared by Task Group 20 of the AAPM Radiation Therapy Committee. Report 16 provides guidelines for the dosimetry oftherapy beams for heavy charged particles including protons and heavier ions. Although the report cites deficiencies in the basic data necessary to provide a desired level of accuracy in dosimetry, it has served as a valuable working document for dosimetry standardization. The European Clinical Heavy Particle Dosimetry Group (ECHED) published a "Code of Practice for Clinical Proton Dosimetry" in 1991 (Vynckier et al., 1991 and a more recent supplement (Vynckier et al., 1994) . This code of practice recommends techniques for determination of absorbed dose to tissue for clinical proton beams.
This Report is more comprehensive than any single document currently available. It is intended to serve as a complete and self-contained reference for determination of absorbed dose in proton beams as used in clinical practice.
